BS_TG93XC55
Ganglioglioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Ganglioglioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Ganglioglioma
- overall_survival_months
- 57.72010512483574
- age_years
- 3.948
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.435
- PANCREAS_BETA_CELLS+0.399
- SPERMATOGENESIS+0.283
- HEDGEHOG_SIGNALING+0.254
- APICAL_SURFACE+0.153
- ESTROGEN_RESPONSE_EARLY+0.130
- OXIDATIVE_PHOSPHORYLATION+0.095
- MYOGENESIS+0.094
- UV_RESPONSE_DN+0.052
- ESTROGEN_RESPONSE_LATE+0.038
Top 10 suppressed
- E2F_TARGETS-0.598
- MYC_TARGETS_V1-0.561
- MYC_TARGETS_V2-0.561
- G2M_CHECKPOINT-0.543
- INTERFERON_ALPHA_RESPONSE-0.537
- ANGIOGENESIS-0.531
- INTERFERON_GAMMA_RESPONSE-0.527
- IL6_JAK_STAT3_SIGNALING-0.481
- DNA_REPAIR-0.477
- UNFOLDED_PROTEIN_RESPONSE-0.467
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
1 twin match this tumor's tissue · 9 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_WCRKYV0T | low-grade glioma | — | 0.987 |
| 2 | BS_AJ6X83G5 | DNET | — | 0.974 |
| 3 | SRR1317877 | GTEX | — | 0.968 |
| 4 | BS_M1PVEHCM | high-grade glioma | — | 0.967 |
| 5 | SRR1434526 | GTEX | — | 0.960 |
| 6 | SRR1318163 | GTEX | — | 0.960 |
| 7 | SRR1470703 | GTEX | — | 0.957 |
| 8 | SRR614647 | GTEX | — | 0.956 |
| 9 | SRR1474951 | GTEX | — | 0.955 |
| 10 | BS_MF47B9ZW | Ganglioglioma | — | 0.955 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.435 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.399 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.283 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.254 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.153 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.095 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.094 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.052 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.038 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.026 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.014 | Inavolisib | — uncovered |